Table 5.
Summary of patients improving efficacy variables on lumiracoxib and ibuprofen treatment at week 4 in subgroups of patients receiving angiotensin receptor blockers or an angiotensin-converting enzyme inhibitor monotherapy (ITT population)
| Patients improving score [n/N (%)] |
||||
|---|---|---|---|---|
| Parameter | Lumiracoxib 100 mg od | Ibuprofen 600 mg tid | Odds ratio (95% CI) | p-Value |
| OA pain | ||||
| ARB monotherapy | 35/56 (62.5) | 33/47 (70.2) | Not calculable* | 0.531* |
| ACEI monotherapy | 31/41 (75.6) | 21/39 (53.8) | 3.05 (1.1, 8.4) | 0.032 |
| Patient’s global assessment of disease activity | ||||
| ARB monotherapy | 33/56 (58.9) | 28/47 (59.6) | 0.61 (0.2, 1.6) | 0.298 |
| ACEI monotherapy | 25/41 (61.0) | 18/39 (46.2) | Not calculable* | 0.262* |
| Physician’s global assessment of disease activity | ||||
| ARB monotherapy | 36/56 (64.3) | 31/47 (66.0) | Not calculable* | > 0.999* |
| ACEI monotherapy | 24/41 (58.5) | 21/39 (53.8) | 1.03 (0.3, 3.0) | 0.955 |
In this analysis, treatment was the main effect and respective baseline variable was the covariate.
*
If the model did not converge, the p-value was obtained using Fisher’s exact test.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CI, confidence interval; ITT, intention-to-treat; od, once daily; tid, thrice daily.